Content about Herpes

April 4, 2013
Valeant earnings per share could take hit in 2013 from herpes ointment generic

The Food and Drug Administration approval this week of a generic genital herpes ointment made by Mylan could make a slight dent in the stock price of the company that makes the branded version.

MONTREAL — The Food and Drug Administration approval this week of a generic genital herpes ointment made by Mylan could make a slight dent in the stock price of the company that makes the branded version.

Canada-based Valeant Pharmaceuticals International said that while it expected Mylan to receive approval for a generic version of Zovirax (acyclovir) ointment, it did not include the approval in its original budget expectations and thus expected its earnings per share in fiscal year 2013 to be reduced by 30 to 40 cents.

April 3, 2013
FDA approves Mylan genital herpes ointment

The Food and Drug Administration has approved a new drug for genital herpes made by Mylan, the drug maker said.

PITTSBURGH — The Food and Drug Administration has approved a new drug for genital herpes made by Mylan, the drug maker said Wednesday.

Mylan announced the approval of acyclovir ointment in the 5% strength. The drug is a generic version of Valeant International's Zovirax, used to manage initial genital herpes and in limited, non-life-threatening mucocutaneous herpes simplex virus infections in patients with compromised immune systems.

December 6, 2012
GSK Consumer Healthcare hires Olympic gold medalist in cold sores campaign

The consumer health division of GlaxoSmithKline has enlisted an Olympic gold medalist to educate the public about cold sores and promote its OTC cold sore treatment.

PARSIPPANY, N.J. — The consumer health division of GlaxoSmithKline has enlisted an Olympic gold medalist to educate the public about cold sores and promote its OTC cold sore treatment.

December 16, 2011
STDs becoming more prevalent across baby boomer demographic

According to an article in the November/December issue of the journal Medical-Surgical Nursing, rates of HIV/AIDS, herpes, syphilis, human papilloma virus and other STDs are climbing steadily across men and women older than 50 years.

PITMAN, N.J. — According to an article in the November/December issue of the journal Medical-Surgical Nursing, rates of HIV/AIDS, herpes, syphilis, human papilloma virus and other STDs are climbing steadily across men and women older than 50 years. 

August 18, 2011
Forces of Nature launches line of topical homeopathics

Forces of Nature on Wednesday introduced its brand called Control, featuring 14 USDA-certified organic and Food and Drug Administration-registered topical medicines that target seven hard-to-treat conditions, including acne, herpes cold sores (caused by the herpes simplex virus) and scars.

SONOMA, Calif. — Forces of Nature on Wednesday introduced its brand called Control, featuring 14 USDA-certified organic and Food and Drug Administration-registered topical medicines that target seven hard-to-treat conditions, including acne, herpes cold sores (caused by the herpes simplex virus) and scars. Each medicine uses a two-in-one approach that merges botanicals with recognized and established homeopathic drugs. The Control line is currently available at select Whole Foods Market stores and is rolling out in independent natural retailers nationwide.

March 22, 2011
Watson introduces generic Famvir

A subsidiary of Watson Pharmaceuticals has launched a treatment for herpes infections, the company said Monday.

MORRISTOWN, N.J. — A subsidiary of Watson Pharmaceuticals has launched a treatment for herpes infections, the company said Monday.

Watson Labs launched famciclovir tablets in the 125-mg, 250-mg and 500-mg strengths. The drug is a generic version of Novartis’ Famvir and is used to treat cold sores and genital herpes in patients with and without HIV.

Famvir and generic versions had sales of about $197 million in 2010, according to IMS Health.

March 1, 2011
Cold sore treatment Xerese enters market

Meda has launched a new cold sore treatment made by commercialization partner Medivir, Medivir said Tuesday.

HUDDINGE, Sweden — Meda has launched a new cold sore treatment made by commercialization partner Medivir, Medivir said Tuesday.

The Swedish drug maker launched Xerese (acyclovir and hydrocortisone), a topical combination product designed to treat recurrent herpes simplex labialis.

Medivir said the U.S. market for cold sore products is $230 million, and it expected the drug to be successful, given Meda’s presence in the U.S. market.

September 29, 2010
GSK halts Simplirix trial

British drug maker GlaxoSmithKline has stopped a late-stage trial of a vaccine for genital herpes,...

LONDON British drug maker GlaxoSmithKline has stopped a late-stage trial of a vaccine for genital herpes, citing disappointing results, GSK said Thursday.

 

April 18, 2010
Break away from outbreaks

Merix Pharmaceutical unveiled its new Fast-Results! genital herpes treatment March 1. The only over-the-counter treatment...

BARRINGTON, Ill. —Merix Pharmaceutical unveiled its new Fast-Results! genital herpes treatment March 1. The only over-the-counter treatment for genital herpes, Fast-Results! answers an unmet need of people who suffer painful symptoms associated with genital herpes outbreaks, and it can be used in conjunction with a prescription therapy for genital herpes.

March 11, 2010
Merix unveils new over-the-counter genital herpes treatment

Merix Pharmaceutical unveiled its new Fast-Results! genital herpes treatment this month while attending the ECRM...

BARRINGTON, Ill. Merix Pharmaceutical unveiled its new Fast-Results! genital herpes treatment this month while attending the ECRM Cough, Cold and Allergy conference in Dallas.

The only OTC treatment for genital herpes, Fast-Results! answers an unmet need of people who suffer painful symptoms associated with genital herpes outbreaks. Designed to be used in conjunction with prescription medication, Fast-Results! also brings needed treatment to consumers who cannot afford prescription medication.

March 8, 2010
New CDC study shows herpes remains prevalent in United States

Approximately 1-in-6 Americans (16.2%) between the ages of 14 and 49 years is infected with...